– USA, MA – Centessa Pharmaceuticals today announced the appointment of Carol Stuckley to its Board of Directors as Chairperson of the Audit Committee.
The company also announced key additions to its leadership team with the appointments of Tia Bush, Chief Quality Officer; Dr. David Chao, Ph.D., Chief Administrative Officer; and Dr. Thomas Templeman, Ph.D., CTO.
Each of their respective roles will support Centessa’s asset-centric R&D model and the continued advancement of the Company’s portfolio of programs.
“We launched Centessa earlier this year with a bold vision focused on reimagining the traditional pharmaceutical research and development model in order to discover, develop and ultimately deliver impactful medicines to patients,” said CEO, Dr. Saurabh Saha. “Successful execution of that vision requires a robust team of like-minded, highly specialized individuals who have the know-how to get things done and bring new ideas. We are thrilled to strengthen our team with the appointments of these exceptional leaders. Each will provide significant expertise in their respective functions. I look forward to partnering with them as we deploy this model, aimed at impacting the lives of patients and society more broadly.”
About Carol Stuckley
Carol Stuckley is a global, strategic financial executive with proven success leading finance teams and creating shareholder value for healthcare companies. Ms. Stuckley was formerly CFO and SVP at HPS and managed its acquisition by TransUnion, Inc. Previously, Ms. Stuckley served as CFO, VP, Finance at Galderma North America. Ms. Stuckley held a nearly 23-year tenure in multinational financial roles of increasing responsibility at Pfizer, most recently as Assistant Treasurer, VP, Finance, and Corporate Officer. She currently sits on the Ipsen Board of Directors and serves as Chairperson of the Audit Committee.
Ms. Stuckley holds a Master of Arts in economics and an MBA in international finance from Temple University’s Fox Business School, and a BA in Economics and French from the University of Delaware.
About Tia Bush
Tia Bush, Chief Quality Officer, brings nearly 30 years of biotechnology quality experience to Centessa. Ms. Bush’s career has been spent in quality-related roles of increasing responsibility at Amgen, which she joined in 1993. Most recently, Ms. Bush was Chief Quality Officer and Senior Vice President, Global Quality/Environment, Health, Safety, and Sustainability, in which role she was responsible for developing, maintaining, and continuously improving the quality management and EHSS management systems. She led an organization of more than 1,400 quality and safety professionals. Ms. Bush currently sits on the Board of Directors for Parenteral Drug Association and USC Health Services. She holds a B.A. in biological sciences with a minor in chemistry from the University of Southern California, Los Angeles.
About Dr. David Chao
David Chao, Ph.D., Chief Administrative Officer, joins Centessa from the Stowers Institute for Medical Research and BioMed Valley Discoveries where he served as President and Chief Executive Officer of both entities. Previously, he was the President of The Graduate School of the Stowers Institute for Medical Research, a member of the Board of Directors for the American Century Companies, Head of Strategic Alliances Global Operations at the Novartis Institutes of BioMedical Research, and a consultant in McKinsey & Company’s Pharmaceutical and Medical Product Practice. Dr. Chao holds a Ph.D. in Biology from M.I.T. and a combined A.M. and A.B. in Biology from Harvard University.
About Dr. Thomas Templeman,
Thomas Templeman, Ph.D., Chief Technology Officer, joins the company from Nuvation Bio, where he served as Senior Vice President, Pharmaceutical Operations and Quality. He previously served as Chief Operating Officer of Graybug Vision and SVP, Pharmaceutical Operations and Quality Assurance at Axovant Sciences. Earlier, Dr. Templeman served as SVP of Pharmaceutical Operations and Quality at Medivation, Vice President of Manufacturing Science and Technology at Hospira, Senior Vice President, Integrated Supply Chain at Liquidia Technologies, and in various leadership roles at Johnson & Johnson, where he worked for 13 years in several capacities. Dr. Templeman earned a B.S. in biology from the University of Santa Clara, a Ph.D. in biological sciences from Dartmouth College, and was a post-doctoral fellow at Harvard University.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of programs led by industry-leading teams. Each program is developed by one of ten Centessa subsidiaries and supported by centralized infrastructure and the Centessa management team.
For more information: https://www.centessa.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
